T cell co-stimulation and co-inhibition in cardiovascular disease: a double-edged sword (Q63915433)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30770894%20AND%20SRC:MED&resulttype=core&format=json

23 April 2020

title

T cell co-stimulation and co-inhibition in cardiovascular disease: a double-edged sword (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30770894%20AND%20SRC:MED&resulttype=core&format=json

23 April 2020

main subject

cardiovascular disease

1 reference

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30770894%20AND%20SRC:MED&resulttype=core&format=json

23 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30770894%20AND%20SRC:MED&resulttype=core&format=json

23 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30770894%20AND%20SRC:MED&resulttype=core&format=json

23 April 2020

Alwin de Jong

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30770894%20AND%20SRC:MED&resulttype=core&format=json

23 April 2020

Ramon Arens

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30770894%20AND%20SRC:MED&resulttype=core&format=json

23 April 2020

Karin H Simons

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30770894%20AND%20SRC:MED&resulttype=core&format=json

23 April 2020

language of work or name

English

0 references

publication date

1 June 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30770894%20AND%20SRC:MED&resulttype=core&format=json

Nature Reviews Cardiology

23 April 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30770894%20AND%20SRC:MED&resulttype=core&format=json

23 April 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30770894%20AND%20SRC:MED&resulttype=core&format=json

23 April 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30770894%20AND%20SRC:MED&resulttype=core&format=json

23 April 2020

page(s)

325-343

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30770894%20AND%20SRC:MED&resulttype=core&format=json

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

23 April 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Molecular regulation of effector and memory T cell differentiation

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

A Theory of Self-Nonself Discrimination: Paralysis and induction involve the recognition of one and two determinants on an antigen, respectively

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

A new analysis of allogeneic interactions

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Molecular interactions of coreceptor CD8 and MHC class I: the molecular basis for functional coordination with the T-cell receptor

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Molecular coordination of alphabeta T-cell receptors and coreceptors CD8 and CD4 in their recognition of peptide-MHC ligands

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Activation and inhibition of lymphocytes by costimulation

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Signals required for programming effector and memory development by CD8+ T cells

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Regulation of innate CD8+ T-cell activation mediated by cytokines

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Cytotoxic T-cell memory without antigen

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Virus-specific CD8+ T-cell memory determined by clonal burst size

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Bystander stimulation of activated CD4+ T cells of unrelated specificity following a booster vaccination with tetanus toxoid.

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

CD28/B7 system of T cell costimulation

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Co-stimulation in T cell responses.

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

CD28 days later: Resurrecting costimulation for CD8(+) memory T cells

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

CD28 Costimulation: From Mechanism to Therapy

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

The TNF Receptor Superfamily in Co-stimulating and Co-inhibitory Responses

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

The B7-CD28 superfamily

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

TNF/TNFR family members in costimulation of T cell responses

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

The B7 family revisited

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Introduction to checkpoint inhibitors and cancer immunotherapy.

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Costimulatory and Coinhibitory Receptor Pathways in Infectious Disease

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Inhibitory receptors on lymphocytes: insights from infections

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

The blockade of immune checkpoints in cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Molecular mechanisms of T cell co-stimulation and co-inhibition

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

The diverse functions of the PD1 inhibitory pathway

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Immune checkpoint blockade: a common denominator approach to cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Immune modulation in cancer with antibodies

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Immune Checkpoint Inhibitors and Cardiac Toxicity: An Emerging Issue

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Fulminant Myocarditis with Combination Immune Checkpoint Blockade

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy.

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

CD27 and CD70 in T cell and B cell activation

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Expression of the murine CD27 ligand CD70 in vitro and in vivo.

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Covalent dimerization of CD28/CTLA-4 and oligomerization of CD80/CD86 regulate T cell costimulatory interactions

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

T cell costimulatory and coinhibitory pathways in vascular inflammatory diseases

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Vascular remodeling in transplant vasculopathy

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Requirement for T-cell apoptosis in the induction of peripheral transplantation tolerance.

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

A theoretical framework for quantitative analysis of the molecular basis of costimulation.

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Chronic cardiac rejection in the LEW to F344 rat model. Blockade of CD28-B7 costimulation by CTLA4Ig modulates T cell and macrophage activation and attenuates arteriosclerosis

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

CD28-B7-mediated T cell costimulation in chronic cardiac allograft rejection: differential role of B7-1 in initiation versus progression of graft arteriosclerosis

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Costimulatory function and expression of CD40 ligand, CD80, and CD86 in vascularized murine cardiac allograft rejection

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Association of B7-1 co-stimulation with the development of graft arterial disease. Studies using mice lacking B7-1, B7-2, or B7-1/B7-2.

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

T cell costimulation blockade blunts pressure overload-induced heart failure

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Costimulatory molecules in human atherosclerotic plaques: an indication of antigen specific T lymphocyte activation

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Evidence for the involvement of T cell costimulation through the B-7/CD28 pathway in atherosclerotic plaques from apolipoprotein E knockout mice

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Monocyte-derived dendritic cells of patients with coronary artery disease show an increased expression of costimulatory molecules CD40, CD80 and CD86 in vitro

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Towards non-invasive imaging of vulnerable atherosclerotic plaques by targeting co-stimulatory molecules.

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

T-cell costimulation and coinhibition in atherosclerosis.

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

B7-1/B7-2 costimulation regulates plaque antigen-specific T-cell responses and atherogenesis in low-density lipoprotein receptor-deficient mice

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

T-cell co-stimulation by CD28-CD80/86 and its negative regulator CTLA-4 strongly influence accelerated atherosclerosis development

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

CTLA4-IgG ameliorates homocysteine-accelerated atherosclerosis by inhibiting T-cell overactivation in apoE(-/-) mice.

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Overexpression of Cytotoxic T-Lymphocyte-Associated Antigen-4 Prevents Atherosclerosis in Mice

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Natural regulatory T cells control the development of atherosclerosis in mice

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4.

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

B-cell surface antigen B7 provides a costimulatory signal that induces T cells to proliferate and secrete interleukin 2.

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Complementarity determining region 1 (CDR1)- and CDR3-analogous regions in CTLA-4 and CD28 determine the binding to B7-1.

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Autoantibodies against cardiac troponin I are responsible for dilated cardiomyopathy in PD-1-deficient mice

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

PD-1 protects against inflammation and myocyte damage in T cell-mediated myocarditis

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

PD-1 deficiency results in the development of fatal myocarditis in MRL mice

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Programmed death ligand 1 regulates a critical checkpoint for autoimmune myocarditis and pneumonitis in MRL mice

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

PD-L1 Prevents the Development of Autoimmune Heart Disease in Graft-versus-Host Disease

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Programmed cell death-1 deficiency exacerbates T cell activation and atherogenesis despite expansion of regulatory T cells in atherosclerosis-prone mice

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Impairment of the programmed cell death-1 pathway increases atherosclerotic lesion development and inflammation

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Proatherogenic immune responses are regulated by the PD-1/PD-L pathway in mice.

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Combination cancer immunotherapy and new immunomodulatory targets

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

ICOS Co-Stimulation: Friend or Foe?

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

A functional role for inducible costimulator (ICOS) in atherosclerosis

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Impaired regulatory T-cell response and enhanced atherosclerosis in the absence of inducible costimulatory molecule.

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Regulation of CD4 T cell activation and effector function by inducible costimulator (ICOS).

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Inducible Co-Stimulator (ICOS) as a potential therapeutic target for anti-cancer therapy.

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

T cell Ig and mucin domain proteins and immunity

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

The TIM gene family: emerging roles in immunity and disease

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Cutting edge: cross-regulation by TLR4 and T cell Ig mucin-3 determines sex differences in inflammatory heart disease

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Associations Between TIM1 Polymorphisms and Dilated Cardiomyopathy in a Han Chinese Population

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Use of a proximity extension assay proteomics chip to discover new biomarkers for human atherosclerosis

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Association between the TIMD4-HAVCR1 variants and serum lipid levels, coronary heart disease and ischemic stroke risk and atorvastatin lipid-lowering efficacy

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Blockade of Tim-1 and Tim-4 Enhances Atherosclerosis in Low-Density Lipoprotein Receptor-Deficient Mice

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Cutting edge: T cell Ig mucin-3 reduces inflammatory heart disease by increasing CTLA-4 during innate immunity

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

SLAM receptors and SAP influence lymphocyte interactions, development and function

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Novel candidate genes in unstable areas of human atherosclerotic plaques.

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Genes involved in systemic and arterial bed dependent atherosclerosis--Tampere Vascular study

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Butyrophilins: an emerging family of immune regulators

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Butyrophilin-like 2 modulates B7 costimulation to induce Foxp3 expression and regulatory T cell development in mature T cells

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

A butyrophilin family member critically inhibits T cell activation

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Regulation of costimulation in the era of butyrophilins

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Cytokines and chemokines: At the crossroads of cell signalling and inflammatory disease

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

The multifaceted roles of TRAFs in the regulation of B-cell function.

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

CD27 costimulation augments the survival and antitumor activity of redirected human T cells in vivo

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Frequency of naturally-occurring regulatory T cells is reduced in patients with ST-segment elevation myocardial infarction.

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

CD70 limits atherosclerosis and promotes macrophage function.

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

CD70-driven chronic immune activation is protective against atherosclerosis

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

The role of CD27-CD70-mediated T cell co-stimulation in vasculogenesis, arteriogenesis and angiogenesis.

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Phase I Dose-Escalation Study of the Anti-CD70 Antibody ARGX-110 in Advanced Malignancies

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

OX40 is a potent immune-stimulating target in late-stage cancer patients

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

OX40 ligand levels and high-sensitivity C-reactive protein levels in blood from local coronary plaque and the femoral artery in patients with acute coronary syndrome or stable angina

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Evaluation of serum soluble OX40 ligand as a prognostic indicator in acute coronary syndrome patients

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Upregulation of OX40-OX40 ligand system on T lymphocytes in patients with acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

High levels of costimulatory receptors OX40 and 4-1BB characterize CD4+CD28null T cells in patients with acute coronary syndrome.

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

OX40 regulates pressure overload-induced cardiac hypertrophy and remodelling via CD4+ T-cells

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Interruption of the OX40-OX40 ligand pathway in LDL receptor-deficient mice causes regression of atherosclerosis

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Plaque Neovascularization Is Increased in Ruptured Atherosclerotic Lesions of Human Aorta

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

The lamina adventitia is the major site of immune cell accumulation in standard chow-fed apolipoprotein E-deficient mice

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Plaque angiogenesis and intraplaque hemorrhage in atherosclerosis.

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Plaque angiogenesis and its relation to inflammation and atherosclerotic plaque destabilization.

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

OX40 ligand plays an important role in the development of atherosclerosis through vasa vasorum neovascularization

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Blockade of OX40/OX40 ligand to decrease cytokine messenger RNA expression in acute renal allograft rejection in vitro

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Nasal cardiac myosin peptide treatment and OX40 blockade protect mice from acute and chronic virally-induced myocarditis

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Interruption of the Tnfrsf4/Tnfsf4 (OX40/OX40L) pathway attenuates atherogenesis in low-density lipoprotein receptor-deficient mice.

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Involvement of OX40 ligand+ mast cells in chronic GVHD after allogeneic hematopoietic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Targeting the CD134-CD134L interaction using anti-CD134 and/or rhCD134 fusion protein as a possible strategy to prevent lupus nephritis

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

4-1BB (CD137), an inducible costimulatory receptor, as a specific target for cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Enhanced levels of soluble and membrane-bound CD137 levels in patients with acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Clinical implications of elevated serum soluble CD137 levels in patients with acute coronary syndrome

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Measurements of Carotid Intima-Media Thickness and of Interadventitia Common Carotid Diameter Improve Prediction of Cardiovascular Events

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Human genetic evidence for involvement of CD137 in atherosclerosis

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

CD137 is expressed in human atherosclerosis and promotes development of plaque inflammation in hypercholesterolemic mice

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

CD137 (4-1BB) deficiency reduces atherosclerosis in hyperlipidemic mice.

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Phase I Study of Single-Agent Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Patients with Advanced Cancer.

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Boosting Cancer Immunotherapy with Anti-CD137 Antibody Therapy.

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Phase Ib Study of Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Combination with Pembrolizumab (MK-3475) in Patients with Advanced Solid Tumors

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Expression of tumor necrosis factor ligand superfamily costimulatory molecules CD27L, CD30L, OX40L and 4-1BBL in the heart of patients with acute myocarditis and dilated cardiomyopathy

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Interference of the CD30-CD30L pathway reduces atherosclerosis development

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Immune checkpoint proteins: exploring their therapeutic potential to regulate atherosclerosis

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Reverse signaling initiated from GITRL induces NF-kappaB activation through ERK in the inflammatory activation of macrophages

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Constitutive GITR Activation Reduces Atherosclerosis by Promoting Regulatory CD4+ T-Cell Responses-Brief Report

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Glucocorticoid-induced TNF receptor-triggered T cells are key modulators for survival/death of neural stem/progenitor cells induced by ischemic stroke

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Control of autoimmune myocarditis and multiorgan inflammation by glucocorticoid-induced TNF receptor family-related protein(high), Foxp3-expressing CD25+ and CD25- regulatory T cells

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Platelet CD40L mediates thrombotic and inflammatory processes in atherosclerosis

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

The role of CD40 and CD154/CD40L in dendritic cells

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Upregulation of CD40-CD40 ligand (CD154) in patients with acute cerebral ischemia.

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Both early and delayed anti-CD40L antibody treatment induces a stable plaque phenotype

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for CD40-CD40 ligand signaling in atherosclerosis

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Deficient CD40-TRAF6 signaling in leukocytes prevents atherosclerosis by skewing the immune response toward an antiinflammatory profile

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Targeting CD40-Induced TRAF6 Signaling in Macrophages Reduces Atherosclerosis.

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Efficacy and safety assessment of a TRAF6-targeted nanoimmunotherapy in atherosclerotic mice and non-human primates

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Blocking CD40-TRAF6 interactions by small-molecule inhibitor 6860766 ameliorates the complications of diet-induced obesity in mice.

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Blocking CD40-TRAF6 signaling is a therapeutic target in obesity-associated insulin resistance

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Discovery of small molecule CD40-TRAF6 inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Essential role of TNF receptor superfamily 25 (TNFRSF25) in the development of allergic lung inflammation

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

The TNF-like protein 1A-death receptor 3 pathway promotes macrophage foam cell formation in vitro.

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Signal transduction by DR3, a death domain-containing receptor related to TNFR-1 and CD95

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Involvement of TL1A and DR3 in induction of pro-inflammatory cytokines and matrix metalloproteinase-9 in atherogenesis

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Dimerization of LT R by LT 1 2 is necessary and sufficient for signal transduction

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Structurally Distinct Recognition Motifs in Lymphotoxin-β Receptor and CD40 for Tumor Necrosis Factor Receptor-associated Factor (TRAF)-mediated Signaling

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Targeting lymphocyte activation through the lymphotoxin and LIGHT pathways

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Mouse aorta smooth muscle cells differentiate into lymphoid tissue organizer-like cells on combined tumor necrosis factor receptor-1/lymphotoxin beta-receptor NF-kappaB signaling

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Artery Tertiary Lymphoid Organs Control Aorta Immunity and Protect against Atherosclerosis via Vascular Smooth Muscle Cell Lymphotoxin β Receptors

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Circulating lymphotoxin β receptor and atherosclerosis: observations from the Dallas Heart Study

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Deficiency in lymphotoxin β receptor protects from atherosclerosis in apoE-deficient mice.

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Endothelial Programmed Death-1 Ligand 1 (PD-L1) Regulates CD8 + T-Cell–Mediated Injury in the Heart

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Autoimmune Cardiotoxicity of Cancer Immunotherapy.

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Nivolumab and ipilimumab versus ipilimumab in untreated melanoma

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Smoldering myocarditis following immune checkpoint blockade

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Left Ventricular Dysfunction After Treatment With Ipilimumab for Metastatic Melanoma.

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Apical ballooning and cardiomyopathy in a melanoma patient treated with ipilimumab: a case of takotsubo-like syndrome

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Acute Lymphocytic Myocarditis With Anti-PD-1 Antibody Nivolumab

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Drug-induced myocarditis after nivolumab treatment in a patient with PDL1- negative squamous cell carcinoma of the lung.

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Suspected autoimmune myocarditis and cardiac conduction abnormalities with nivolumab therapy for non-small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors-an autopsy study

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Myocarditis as an immune-related adverse event with ipilimumab/nivolumab combination therapy for metastatic melanoma

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Exploring immune checkpoints as potential therapeutic targets in atherosclerosis

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

CTLA4Ig: bridging the basic immunology with clinical application

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Cardiovascular Toxicities Associated with Cancer Immunotherapies

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Checkpoint inhibitor induced cardiotoxicity: managing the drawbacks of our newest agents against cancer

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Immune checkpoint inhibitor-related myocarditis

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

ESC position paper on cardiovascular toxicity of cancer treatments: challenges and expectations

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Controlled local delivery of CTLA-4 blocking antibody induces CD8+ T-cell-dependent tumor eradication and decreases risk of toxic side effects.

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Regulatory T cells in cardiovascular diseases

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

EACVI/HFA Cardiac Oncology Toxicity Registry in breast cancer patients: rationale, study design, and methodology (EACVI/HFA COT Registry)--EURObservational Research Program of the European Society of Cardiology

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Cytokines in atherosclerosis: pathogenic and regulatory pathways

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Dynamic T cell-APC interactions sustain chronic inflammation in atherosclerosis

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

The role of adaptive T cell immunity in atherosclerosis

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

IL-1R and MyD88 signalling in CD4+ T cells promote Th17 immunity and atherosclerosis

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Systemic Upregulation of IL-10 (Interleukin-10) Using a Nonimmunogenic Vector Reduces Growth and Rate of Dissecting Abdominal Aortic Aneurysm

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

The effect of interleukin-10 knock-out and overexpression on neointima formation in hypercholesterolemic APOE*3-Leiden mice

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Interleukin 10: a new risk marker for the development of restenosis after percutaneous coronary intervention

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Hypercholesterolemia is associated with a T helper (Th) 1/Th2 switch of the autoimmune response in atherosclerotic apo E-knockout mice

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

The role of interleukin-4 and interleukin-12 in the progression of atherosclerosis in apolipoprotein E-deficient mice

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Interleukin-4 deficiency decreases atherosclerotic lesion formation in a site-specific manner in female LDL receptor-/- mice

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Inhibition of IL-17A attenuates atherosclerotic lesion development in apoE-deficient mice

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Blockade of interleukin-17A results in reduced atherosclerosis in apolipoprotein E-deficient mice

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

The IL-17A/IL-17RA axis plays a proatherogenic role via the regulation of aortic myeloid cell recruitment

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Interleukin-17A Deficiency Accelerates Unstable Atherosclerotic Plaque Formation in Apolipoprotein E-Deficient Mice

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Cytotoxic and proinflammatory CD8+ T lymphocytes promote development of vulnerable atherosclerotic plaques in apoE-deficient mice

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Human and Mouse CD8(+)CD25(+)FOXP3(+) Regulatory T Cells at Steady State and during Interleukin-2 Therapy

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Protective and pathogenic roles of CD8(+) T cells in atherosclerosis

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: a clinical and imaging study of abatacept (the ADJUST trial)

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Attainment and characteristics of clinical remission according to the new ACR-EULAR criteria in abatacept-treated patients with early rheumatoid arthritis: new analyses from the Abatacept study to Gauge Remission and joint damage progression in meth

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b, multicentre, randomised, active-controlled AVERT study of 24 months, with a 12-month, double-blind treatment period

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Upregulation of Programmed Death-1 and Its Ligand in Cardiac Injury Models: Interaction with GADD153.

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Requirement for CD154 in the progression of atherosclerosis.

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

Reduction of atherosclerosis in mice by inhibition of CD40 signalling

1 reference

https://api.crossref.org/works/10.1038%2FS41569-019-0164-7

7 January 2021

10.1038/S41569-019-0164-7

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30770894%20AND%20SRC:MED&resulttype=core&format=json

23 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:30770894%20AND%20SRC:MED&resulttype=core&format=json